Cardiac oxidation independently leads to uncoupled cardiac NOS and diastolic dysfunction, suggesting BH(4) as a potential therapeutic target.
May support BH4 as therapeutic target in diastolic dysfunction; hypothesis-generating in animal models only.
Cardiac oxidation, independently of vascular changes, can lead to uncoupled cardiac NOS and diastolic dysfunction. BH(4) may represent a possible treatment for diastolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Silberman et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: